Manidipine-delapril combination in the management of hypertension.
High blood pressure (BP) is the major cardiovascular risk factor and the main cause of death around the world. Control of blood pressure reduces the high mortality associated with hypertension and the most recent guidelines recommend reducing arterial BP values below 140/90 mmHg for all hypertensive patients (130/80 in diabetics) as a necessary step to reduce global cardiovascular risk, which is the fundamental objective of the treatment. To achieve these target BP goals frequently requires combination therapy with two or more antihypertensive agents. Although the combination of a diuretic and an angiotensin converting enzyme inhibitor (ACEI) is the most commonly used in the clinical practice, the combination of an ACEI and a calcium channel blocker may have an additive antihypertensive effect, a favorable effect on the metabolic profile, and an increased target organ damage protection. The new oral fixed combination manidipine 10 mg/delapril 30 mg has a greater antihypertensive effect than both components of the combination separately, and in non-responders to monotherapy with manidipine or delapril the average reduction of systolic and diastolic BP is 16/10 mmHg. The combination is well tolerated and the observed adverse effects are of the same nature as those observed in patients treated with the components as monotherapy. However, combination therapy reduces the incidence of ankle edema in patients treated with manidipine.
Otero
Manuel Luque
ML
Hypertension Unit, Hospital Clinico San Carlos, Complutense University, Madrid, Spain. mluqueo@telefonica.net
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D004095:Dihydropyridines / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007189:Indans / Q000494:pharmacology* / Q000627:therapeutic use; D009578:Nitrobenzenes; D010879:Piperazines
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D007189:Indans; D009578:Nitrobenzenes; D010879:Piperazines; C054218:manidipine; C047759:delapril
J Cardiovasc Pharmacol. 2000 Jun;35(6):926-31
10836728
J Hypertens. 2000 Dec;18(12):1871-5
11132613
Hypertension. 2001 Mar;37(3):943-8
11244022
Ann Intern Med. 2001 Jul 17;135(2):73-87
11453706
J Cardiovasc Pharmacol. 2001 Oct;38(4):642-50
11588535
J Hypertens. 2002 Feb;20(2):159-69
11821696
J Hypertens. 2002 Aug;20(8):1461-4
12172300
J Renin Angiotensin Aldosterone Syst. 2002 Jun;3(2):79-89
12228847
Circulation. 2002 Nov 5;106(19):2422-7
12417537
JAMA. 2002 Dec 18;288(23):2981-97
12479763
Lancet. 2002 Dec 14;360(9349):1903-13
12493255
JAMA. 2003 May 14;289(18):2363-9
12746359
JAMA. 2003 May 21;289(19):2560-72
12748199
J Hypertens. 2003 Jun;21(6):1011-53
12777938
J Cardiovasc Pharmacol. 1992 Dec;20(6):895-9
1282591
BMJ. 2003 Jun 28;326(7404):1427
12829555
Am J Med. 2003 Jul;115(1):41-6
12867233
Arzneimittelforschung. 2003;53(9):627-34
14558436
Lancet. 2003 Nov 8;362(9395):1527-35
14615107
J Hum Hypertens. 2004 Oct;18(10):687-91
15071488
J Hypertens. 2004 Mar;22(3):479-86
15076152
J Hypertens. 2004 Jan;22(1):51-7
15106794
Hypertension. 2004 Jun;43(6):1338-44
15117908
Lancet. 2004 Jun 19;363(9426):2022-31
15207952
Drugs. 2004;64(17):1923-40
15329044
N Engl J Med. 2004 Nov 4;351(19):1941-51
15516697
Clin Ther. 2004 Sep;26(9):1419-26
15531004
J Cardiovasc Pharmacol. 2005 Mar;45(3):241-6
15725949
Clin Ther. 2005 Feb;27(2):166-73
15811479
Arch Intern Med. 2005 Jun 27;165(12):1410-9
15983291
Eur J Clin Pharmacol. 2005 Aug;61(7):483-90
16021438
Blood Press Suppl. 2005 Jul;1:6-13
16060411
Lancet. 2005 Sep 10-16;366(9489):895-906
16154016
J Hypertens. 2006 Jan;24(1):3-10
16331092
Drugs. 2005;65 Suppl 2:21-7
16398059
Lancet. 2006 May 27;367(9524):1747-57
16731270
Am J Hypertens. 1991 Jan;4(1 Pt 2):23S-28S
2009144
J Cardiovasc Pharmacol. 1987;10 Suppl 10:S147-8
2455119
Curr Ther Res Clin Exp. 2003 Jul;64(7):422-33
24944393
Clin Pharmacol Ther. 1988 Mar;43(3):242-9
3345615
J Pharmacol Exp Ther. 1987 Nov;243(2):703-10
3681701
JAMA. 1970 Aug 17;213(7):1143-52
4914579
J Clin Invest. 1995 Aug;96(2):793-800
7635974
J Hum Hypertens. 1994 Feb;8(2):145-9
8207741
Hypertension. 1994 Jan;23(1):83-91
8282334
N Engl J Med. 1993 Nov 11;329(20):1456-62
8413456
J Diabetes Complications. 1995 Oct-Dec;9(4):215-9
8573730
Hypertens Res. 1996 Mar;19(1):31-6
8829821
J Hypertens. 1995 Dec;13(12 Pt 1):1363-75
8866898
Diabetes Res Clin Pract. 1996 Jun;33(1):43-51
8877275
Blood Press Suppl. 1996;5:16-23
8973788
J Hypertens. 1996 Sep;14(9):1139-46
8986916
J Hypertens Suppl. 1997 Mar;15(2):S39-42
9218197
Clin Ther. 1997;19 Suppl A:3-17
9385501
Kidney Int. 1998 Jun;53(6):1559-73
9607186
Lancet. 1998 Jun 13;351(9118):1755-62
9635947
J Hypertens. 1998 Nov;16(11):1667-76
9856368
J Hypertens. 1998 Dec;16(12 Pt 1):1823-9
9869017
N Engl J Med. 1998 Dec 31;339(27):1957-63
9869666